Lenalidomid Hexal (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, triggering degradation of transcription factors Ikaros and Aiolos. This action modifies immune cell activity, inhibits new blood‑vessel formation, and directly suppresses proliferation while promoting apoptosis of malignant cells.

The specific dose of Lenalidomid Hexal is determined by the treating physician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. Prescribers follow approved labeling and adjust dosing as needed for safety and efficacy.

Lenalidomid Hexal is classified as pregnancy category X because it is teratogenic and can cause fetal harm. It should not be used by pregnant women, and effective contraception is required during treatment and for a defined period afterward. Use while breastfeeding is not recommended.

To order Lenalidomid Hexal, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomid Hexal belongs to the immunomodulatory drug (IMiD) class, similar to thalidomide and pomalidomide. Compared with thalidomide, lenalidomide generally offers higher potency with a more favorable peripheral neuropathy profile, while pomalidomide is often reserved for patients who have progressed after lenalidomide therapy.

Lenalidomid Hexal should be stored at ambient temperature below 25 °C, protected from moisture and light. Keep the tablets in the original blister pack until use and avoid exposing them to excessive heat or humidity.

Lenalidomid Hexal is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed.

Serious risks include venous thromboembolism, severe neutropenia or infection, secondary primary malignancies, significant liver toxicity, tumor lysis syndrome, and severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for these events and report any concerning symptoms promptly.

Lenalidomid Hexal should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or any excipients, patients with severe hepatic impairment, or those for whom anticoagulation therapy cannot be safely managed. Clinicians must assess each patient’s risk profile before initiating therapy.